Moderate

Multiple endocrine neoplasia type 1 (MEN1)

MEN1 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Autosomal dominant tumour syndrome (MEN1 gene) predisposing to parathyroid, pancreatic/duodenal neuroendocrine and anterior pituitary tumours. Lifelong biochemical and imaging surveillance detects tumours early.

Red flags

  • Severe hypercalcaemia
  • Refractory peptic ulceration/diarrhoea (gastrinoma)
  • Recurrent hypoglycaemia (insulinoma)
  • Visual field loss (pituitary macroadenoma)
  • Rapidly growing pancreatic/thymic mass

Assessment

Differential diagnosis

  • Sporadic primary hyperparathyroidism
  • MEN2
  • MEN4
  • Sporadic pituitary adenoma
  • Sporadic pancreatic neuroendocrine tumour
  • Hyperparathyroidism-jaw tumour syndrome

Investigations

  • Calcium and PTH (primary hyperparathyroidism)
  • Fasting gut hormones, gastrin, glucose/insulin and chromogranin A
  • Prolactin, IGF-1 and pituitary function
  • Pancreatic/pituitary MRI and functional imaging (DOTATATE)
  • Germline MEN1 genetic testing and family cascade

Management

  • Suspect MEN1 with the triad of parathyroid, pancreatic and pituitary tumours or a suggestive family history
  • Confirm with germline genetic testing and offer cascade testing to relatives
  • Enrol gene carriers in lifelong periodic biochemical and imaging surveillance
  • Manage primary hyperparathyroidism (usually multigland) with subtotal/total parathyroidectomy
  • Control functioning pancreatic tumours: proton pump inhibitors for gastrinoma, surgery for insulinoma
  • Treat pituitary tumours per type (dopamine agonist for prolactinoma, etc.)
  • Watch for malignant potential of pancreatic/thymic neuroendocrine tumours
  • Avoid thymic carcinoid risk awareness (especially male smokers)
  • Coordinate multidisciplinary surgical and oncological care
  • Provide genetic counselling and psychological support

Drugs & doses

Proton pump inhibitor (e.g. high-dose omeprazole) for gastrinoma acid control
Cabergoline for prolactinoma
Somatostatin analogues (octreotide/lanreotide) for neuroendocrine tumours
Cinacalcet if hyperparathyroidism surgery deferred/unsuccessful

Disposition

Lifelong management in a specialist endocrine/neuroendocrine centre with multidisciplinary surgery and genetics-led family screening.

Complications & pitfalls

  • Metastatic pancreatic/duodenal neuroendocrine tumours
  • Zollinger-Ellison syndrome complications
  • Thymic carcinoid (aggressive)
  • Recurrent hyperparathyroidism after surgery
  • Pituitary mass effects

Exam pearls

  • Hyperparathyroidism is usually the earliest and commonest manifestation and is multigland
  • Pancreatic neuroendocrine tumours are the leading cause of MEN1-related death; surveillance is vital
  • Gastrinomas are frequently multiple and located in the duodenum
  • Cascade genetic testing allows pre-symptomatic surveillance of relatives

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.